

[22] 欧开萍,马飞,桑蝶,吕剑虹.依维莫司治疗乳腺癌致间质性肺炎临床分析[J].临床药物治疗杂志,2015,13(4):76-80.

[23] XU B, WU Y, SHEN L, et al. Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors[J]. J Hematol Oncol, 2011, 4(1):1-7.

[24] MOTZER R J, BARRIOS C H, KIM T M, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma[J]. J Clin Oncol, 2014, 32(25):2765-2772.

[25] Teng C F, Wu H C, Tsai H W, et al. Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy[J]. Hepatology, 2011, 54(4):1199-1207.

[26] BASELGA J, CAMPONE M, PICCART M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer[J]. N Engl J Med, 2012, 366(6):520-529.


[27] LEBWOBL D, THOMAS G, H A L, et al. Research and innovation in the development of everolimus for oncology[J]. Expert Opinion on Drug Discovery, 2011, 6:323-338.

[28] WULLSCHLEGER S, LOEWITH R, HALL M N. TOR signaling in growth and metabolism [J]. Cell, 2006, 124(3):471-474.

[29] 江泽飞,徐兵河,邵志敏.乳腺癌内分泌治疗专家共识与争议[J].中国癌症杂志,2013,23(9):772-776.

[30] 武之洋.依维莫司在肿瘤治疗中代谢相关不良反应的系统性综述和荟萃分析[D].山东:山东大学,2015:27-29.

[本文编辑:李彩惠]



· 信 息 ·

2017 年《现代临床护理》订阅订户信息表

工作单位:		邮编:
订阅人姓名:	收件人姓名:	邮编:
收件人地址:		
联系电话(区号):		
汇款金额: 元	汇票收据号:	
汇款方式: <input type="checkbox"/> 邮局报刊发行 <input type="checkbox"/> 邮局个人汇款 <input type="checkbox"/> 编辑部		
备 注:		